5th Circuit reinstates in-person mifepristone dispensing requirement

Plus: Biotech industry recognizes FDA-regulated science over litigation, mifepristone used safely for two decades.

The 5th Circuit Court of Appeals reinstated an in-person dispensing requirement for mifepristone on Friday, challenging the biotech industry's premise that FDA-regulated science determines how medicines reach patients. This action follows an earlier Texas case contesting mifepristone’s Food and Drug Administration approval, despite the drug’s safe use by millions for over two decades. Drug manufacturer Danco appealed to the Supreme Court within hours. Five takes inside, plus a quick-hits roundup.